Cytokine Innovation in IBD Report
Key insights included:
- Rising clinical engagement: IBD-related cytokine research has surged, with 568 trials now tracked on Beacon and 52% of 2025 starts already recruiting.
- Expanding therapeutic landscape: Beacon Cytokine monitors 238 drugs in IBD, 19% approved and 28% in active development.
- Leading targets: TNF-alpha remains the most active cytokine target, with therapies like Infliximab continuing to drive innovation through real-world studies.
- …and much more inside the report!
You May Also Be Interested In…
Learn More About Cytokine
What is Beacon Cytokine?
- The Most Comprehensive Way to Search the Cytokine Drug Development Landscape: Unique search ontologies based on Cytokine drug and trial characteristics
- Market Leading Approach to Cytokine Preclinical & Clinical Data Curation: Manual curation of key Cytokine research and development data points by Cytokine research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Cytokine company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
